跳至主要内容
临床试验/NCT03713931
NCT03713931Unknown不适用

BUSQUEDA ACTIVA DE CASOS DE EPOC EN EL PRIMER NIVEL DE ATENCION: USO DEL SCORE PUMA PARA TAMIZAJE DE EPOC

Gustavo Zabert, MD5 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2018年11月14日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
1,000
试验地点
5
主要终点
COPD prevalence

研究概览

简要总结

COPD is underdiagnosed and spirometry is not widely available in primary care settings. This study explore the value of PUMA´s questionnaire in a case finding strategy to detect patients to perform spirometry in a real world scenario of primary care health venues.

详细描述

PUMA (Prevalence StUdy and Regular Practice, Diagnosis and TreatMent, Among General Practitioners in Populations at Risk of COPD in Latin America) study, a multicenter, multinational, cross-sectional, non-interventionist study, explored COPD prevalence among high risk patients assisted in primary care centers in 4 Latin American countries High risk condition was defined if the patient was older than 40 years and current or former smokers (≥10 pack-years, ≥50 pipes/year, or ≥50 cigars/year), and/or reported exposure to biomass smoke, such as wood or coal, for cooking or heating (exposure ≥100h/year). Patients were enrolled during routine, spontaneous or scheduled visits to their medical appointment neither related with the study nor respiratory services or specialists as well. COPD was defined as post-bronchodilator (post-BD) forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.70 and the lower limit of normal (LLN) of FEV1/FVC.

Based on PUMA study data, a simple and a weighted score was constructed with seven variables: sex, age, pack-years smoking, dyspnea, sputum, cough and previous spirometry selected from the PLATINO questionnaire. The score had a mean accuracy for detecting COPD (post-BD FEV1/FVC <0.70) for high risk population of 76% and 79% for the simple and weighted scores, respectively.

This study is a prospective case finding study based on PUMA score as screening tool in unselected high risk patients attending to a primary care health care venue in real world scenario (e.g. community hospital, university institutions or other primary care settings). Patients older than 40 years of age and ever smoker of at least 10 pack year will be asked to complete the PUMA questionnaire through an specially designed application and electronic database (RedCap). All patients who with PUMA score ≥ 5, will be referred to perform spirometry at the institution.

Recruitment will be done by primary care physicians during regular consultations for any reason and spirometry will be performed by qualified technicians using the EasyOne® (nnd) spirometer. The quality of the spirometry will be evaluated by the central team that may request a second measurement to satisfy quality.

COPD will be diagnosed with fixed FEV1/FVC ratio (forced expiratory volume in the first second or FEV1 divided by forced vital capacity or FVC) less than 0.7.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
40 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients who attend the first level of care for any reason in usual care
  • Informed consent: subjects must give their signed and dated informed consent to participate.
  • Age older 40 years of age
  • Smoker or ex-smoker of more than 10 years package

排除标准

  • pregnancy,
  • patients with contraindication for spirometry (thoracic, abdominal or neurological surgery,
  • acute coronary syndrome, retinal detachment, hospitalization for any cardiac problem in the last 3 months)
  • patients who at the time of performing the spirometry heart rate ≥ 120 bpm,
  • patients with physical or mental incapacity to answer the questionnaire
  • patients with physical or mental disability complete the study procedures,
  • patients being treated for tuberculosis or any other infectious respiratory disease
  • current participants of a clinical trial.

结局指标

主要结局

COPD prevalence

时间窗: 2 days

FEV1 / FVC post-BD \<0.70

次要结局

  • PUMA ≥ 5 prevalence(1 day)

研究者

发起方
Gustavo Zabert, MD
申办方类型
Industry
责任方
Sponsor Investigator
主要研究者

Gustavo Zabert, MD

Professor, MD

Asociacion Latinoamericana de Torax

研究点 (5)

Loading locations...

相似试验